Table 2.

Criteria for an ideal biomarker[13]

Should detect a fundamental feature of the molecular pathogenesis or neuropathology of AD Should be validated in neuropathologically confirmed AD cases Should have a sensitivity >80% for detecting AD and a specificity >80% for differentiating AD from other dementias Should be able to detect AD in its early stages (i.e., during MCI) Be reliable, reproducible, noninvasive, simple to perform, inexpensive and, thus, adaptable in routine clinical practice